jetcityimage/iStock Editorial via Getty Images
- The U.S. FDA has granted orphan drug designation for Eli Lilly’s olomorasib for treatment of KRAS G12C-mutant non-small cell lung cancer.
- The candidate is in phase 3 for this indication. It is under examination for KRAS G12C-mutated cancers in combination with Keytruda (pembrolizumab) with or without chemotherapy for first-line treatment of advanced NSCLC.
- Earlier this month at the ASCO annual conference, Lilly presented early-stage data on olomorasib in combination with Erbitux (cetuximab) for KRAS G12C-mutant colorectal cancer.
More on Eli Lilly
- Eli Lilly: It Is A Bet On Human Longevity
- Lilly ADA Investor Presentation
- Eli Lilly and Company (LLY) Presents at Special Call (Lilly Investor Event at American Diabetes Association’s (ADA) 85th Scientific Sessions) Conference Transcript
- Novo Nordisk rolls out weight loss drug Wegovy in India, following Eli Lilly’s Mounjaro launch
- Eli Lilly drug bimagrumab saves muscle mass when added to Novo’s Wegovy